The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
FOX 9 Minneapolis-St. Paul on MSN17h
Generic prescription drug prices marked up as high as 5,000%, investigation findsA new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, finding the companies sometimes increased prices of these drugs by 1,000 ...
The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Dealbreaker on MSN18d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Specifically, the FTC’s first report found Caremark, Express Scripts and Optum Rx were prioritizing access to high-cost drugs in return for larger discounts from drugmakers and giving their own ...
The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback